0.06
-1.72%
Close of 9 Nov 2026, in AUD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Little Green Pharma
Its shares trade on ASX under the ticker LGP.AX. It has been listed since 20 February 2020. In the fiscal year to 30 June 2026, it reported revenue of A$42.4m and a net loss of A$1.4m. At that date it held total assets of A$93.8m and shareholders' equity of A$83.0m.
Little Green Pharma Ltd. produces medicinal cannabis products for sale to Australian patients. The company is headquartered in Perth, Western Australia. The company went IPO on 2020-02-20. The firm has two global production sites for the manufacture of its own-branded and white-label ranges of Good Manufacturing Practice (GMP)-grade medicinal cannabis products, being a 21,500 square meters cultivation and 4,000 square meters GMP manufacturing facility capable of producing over 30 tons of medicinal cannabis biomass per annum located in Denmark (EU) and an indoor cultivation and manufacturing facility located in Western Australia capable of producing three tons of medicinal cannabis biomass per annum. The firm focuses on patient access in the global medicinal cannabis market and is actively engaged in promoting education and outreach programs, as well as participating in clinical investigations and research projects to develop new delivery systems.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 20 Feb 2020
- Website
- littlegreenpharma.com ↗
Leadership
Pay as last reported
- Mr. Michael Lynch-BellNon-Executive Independent Chairman of the BoardA$163,736
- Mr. Paul LongChief Executive Officer, Managing Director, since 2025
- Mr. Angus CaithnessExecutive DirectorA$801,506
- Ms. Fleta SolomonExecutive Director, since 2017A$955,522
- Mr. Alistair WarrenCompany Secretary
- Mr. David FenlonNon-Executive Director
- Dr. Neale FongNon-Executive Independent DirectorA$95,261
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Little Green Pharma operates a 21,500 square meters cultivation facility in Denmark for GMP-grade products.
- The company produces over 30 tons of medicinal cannabis biomass annually at its Danish site.
- Little Green Pharma has a Western Australia facility capable of producing three tons of biomass per annum.
Weaknesses
- The Western Australia facility produces only three tons of medicinal cannabis biomass per annum.
- The company relies on two global production sites for its own-branded and white-label ranges.
- Little Green Pharma focuses on patient access rather than immediate broad market dominance.
Opportunities
- Little Green Pharma is actively engaged in promoting education and outreach programs globally.
- The firm participates in clinical investigations to develop new delivery systems for patients.
- Little Green Pharma promotes education and outreach programs to expand patient access in the global market.
Threats
- Little Green Pharma faces competition in the global medicinal cannabis market for patient access.
- The company must maintain Good Manufacturing Practice standards for its Danish and Australian facilities.
- Little Green Pharma relies on clinical investigations to validate new delivery systems for patients.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.